Raymond James & Associates Intellia Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 178,254 shares of NTLA stock, worth $2.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

178,254

Previous 207,295 14.01%

Holding current value

$2.86 Million

Previous $4.64 Million 21.04%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$19.72 - $27.36 $572,688 - $794,561	-29,041 Reduced 14.01%	178,254 $3.66 Million
Q2 2024 Jul 19, 2024	BUY	$20.02 - $27.22 $1.05 Million - $1.43 Million	52,671 Added 34.06%	207,295 $4.64 Million
Q1 2024 Apr 22, 2024	BUY	$23.82 - $32.8 $482,426 - $664,298	20,253 Added 15.07%	154,624 $4.25 Million
Q4 2023 Jan 16, 2024	BUY	$23.16 - $32.34 $694,730 - $970,102	29,997 Added 28.74%	134,371 $4.1 Million
Q3 2023 Oct 24, 2023	BUY	$31.62 - $45.78 $1.09 Million - $1.58 Million	34,458 Added 49.28%	104,374 $3.3 Million
Q2 2023 Jul 25, 2023	BUY	$34.58 - $46.03 $587,790 - $782,417	16,998 Added 32.12%	69,916 $2.85 Million
Q1 2023 Apr 14, 2023	BUY	$33.3 - $44.82 $1.06 Million - $1.43 Million	31,818 Added 150.8%	52,918 $1.97 Million
Q4 2022 Feb 08, 2023	BUY	$33.21 - $62.69 $91,958 - $173,588	2,769 Added 15.11%	21,100 $736,000
Q3 2022 Oct 25, 2022	BUY	$53.92 - $71.7 $254,340 - $338,208	4,717 Added 34.65%	18,331 $1.03 Million
Q2 2022 Aug 12, 2022	SELL	$38.49 - $76.21 $18,706 - $37,038	-486 Reduced 3.45%	13,614 $705,000
Q1 2022 May 11, 2022	SELL	$58.27 - $118.99 $182,618 - $372,914	-3,134 Reduced 18.18%	14,100 $1.03 Million
Q4 2021 Feb 08, 2022	SELL	$100.76 - $138.36 $1.1 Million - $1.52 Million	-10,952 Reduced 38.86%	17,234 $2.04 Million
Q3 2021 Nov 02, 2021	BUY	$132.37 - $176.78 $475,473 - $634,993	3,592 Added 14.61%	28,186 $3.78 Million
Q2 2021 Aug 11, 2021	SELL	$60.88 - $161.91 $99,417 - $264,399	-1,633 Reduced 6.23%	24,594 $3.98 Million
Q1 2021 May 14, 2021	BUY	$46.59 - $83.68 $367,129 - $659,398	7,880 Added 42.95%	26,227 $2.11 Million
Q4 2020 Feb 12, 2021	BUY	$18.83 - $63.53 $98,236 - $331,436	5,217 Added 39.73%	18,347 $998,000
Q3 2020 Nov 04, 2020	SELL	$17.47 - $24.93 $76,064 - $108,545	-4,354 Reduced 24.9%	13,130 $261,000
Q2 2020 Jul 28, 2020	SELL	$11.14 - $22.87 $12,588 - $25,843	-1,130 Reduced 6.07%	17,484 $368,000
Q1 2020 Apr 21, 2020	BUY	$9.44 - $15.58 $3,304 - $5,453	350 Added 1.92%	18,614 $228,000
Q4 2019 Feb 12, 2020	BUY	$10.43 - $17.67 $190,493 - $322,724	18,264 New	18,264 $268,000
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $223,976 - $283,228	-8,688 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$20.02 - $30.79 $76,856 - $118,202	-3,839 Reduced 30.65%	8,688 $238,000
Q1 2018 May 14, 2018	BUY	$19.43 - $34.95 $243,399 - $437,818	12,527 New	12,527 $264,000

Others Institutions Holding NTLA

# of Institutions

318

Shares Held

88.5M

Call Options Held

668K

Put Options Held

865K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.22B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Intellia Therapeutics, Inc. Transaction History